OXB

Trademark usage description

custom manufacture of products relating to biotechnology; manufacture of gene therapy, and viral, retroviral, lentiviral and non-viral preparations an Read More

Classification Information

Class [040]
Custom manufacture of products relating to biotechnology; manufacture of gene therapy, and viral, retroviral, lentiviral and non-viral preparations and biopharmaceutical products; biotechnology contract manufacturing services; contract manufacturing of viral and non-viral vectors; manufacture of vaccines.

Classification kind code

Class [042]
Research and laboratory analytic and diagnostic services; design of manufacturing facilities; quality control and validation services; product development consultancy in the field of nanotechnology, gene therapy and vector-based delivery systems; product, viral vector and analytic assay development for others; laboratory services; research and development services; genetic engineering laboratories and biochemistry laboratories; scientific and technological services and research; industrial analysis services; provision of information relating to scientific research; provision of scientific information; research and scientific analysis relating to drug discovery and development for others; scientific advisory services; scientific consultancy; scientific research and development; scientific research in the field of biotechnology and pharmaceuticals; management of scientific research projects; issuing of scientific information; advisory services relating to scientific and clinical research; biological research, clinical research and medical research; clinical research; conducting clinical trials; manufacturing development services.

Classification kind code

Mark Details

Serial Number

2333258

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 287 on 27^th Jun 2024	Pre-Assessment Letter Sent
Submitted for opposition 30 on 17^th Jun 2024	Filed
Submitted for opposition 1 on 17^th Jun 2024	Created
Submitted for opposition 31 on 17^th Jun 2024	Formalized